Last reviewed · How we verify

Crohn's disease in remission — Treatment Landscape & Competitive Intelligence

Crohn's disease in remission (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Crohn's disease in remission, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pulmicort Respules BUDESONIDE AstraZeneca K.K. Corticosteroid [EPC] Glucocorticoid receptor 1994-01-01
Verdeso DESONIDE Padagis Us Corticosteroid [EPC] Glucocorticoid receptor 1972-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AstraZeneca K.K. · 1 drug in Crohn's disease in remission
  2. Padagis Us · 1 drug in Crohn's disease in remission

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Crohn's disease in remission:

Cite this brief

Drug Landscape (2026). Crohn's disease in remission — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/crohn-s-disease-in-remission. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing